PathAI
AI-powered pathology platform to improve patient outcomes through precision diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
AI-powered pathology algorithmsLarge proprietary pathologist contributor network (450+ board-certified pathologists)Extensive annotation dataset (32.5M+ annotations)FDA-cleared digital pathology platform (AISight® Dx)CE-IVDR marked platformBiomarker discovery and drug development supportCloud-native open platform enterprise workflow (AISight®)
Enterprise pricing
Boston, USA
Founded 2016
Facts verified against pathai.com on
Get alerts when PathAI changes
Free. We'll email you when pricing, the free tier, API access or open-source status changes.
No ratings yet
PathAI – Technical Use Cases
- Clinical Deployment of AI Pathology Algorithms: Institutions can deploy FDA-cleared AI algorithms via AISight® Dx within compliant clinical workflows, supporting diagnostic decision-making in anatomic pathology.
- Enterprise Workflow Integration: AISight®'s cloud-native, open architecture enables academic medical centers, reference laboratories, and health systems to integrate AI pathology tools into existing LIS/digital pathology infrastructure.
- Multi-Algorithm Environments: Via integrations with Deep Bio, Paige, Visiopharm, and DoMore Diagnostics, technical teams can orchestrate multiple third-party AI algorithms within a single platform environment.
- BioPharma Drug Development & Biomarker Discovery: PathAI's annotation dataset and AI algorithms can be applied to computational pathology pipelines supporting biomarker identification, patient stratification, and clinical trial tissue analysis.
- Large-Scale Annotation & Model Training: The 32.5M+ annotation corpus and 450+ pathologist contributor network represent infrastructure that BioPharma and research teams can leverage for AI model development and validation.
Alternatives
See all alternatives